Filing Details

Accession Number:
0001209191-23-047137
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-23 20:08:50
Reporting Period:
2023-08-21
Accepted Time:
2023-08-23 20:08:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
914475 Neurocrine Biosciences Inc NBIX Biological Products, (No Disgnostic Substances) (2836) 330525145
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1201096 Charles Kevin Gorman 12780 El Camino Real
San Diego CA 92130
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-08-21 9,328 $107.40 499,754 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Sale of 9,328 shares of common stock issued upon vesting of 17,717 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (8,389) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  2. The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.
  3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.